New York · 51720

Instillation Of Anti-Cancer Drug Into Bladder in New York

New York Medicare Avg
$66.85
10% above national avg
National Medicare Avg
$60.79
All states combined
Billed Charge (NY)
$490.40
What providers submit
Est. Commercial (NY)
$216.14
National avg: $176.32
Est. Cash / Self-Pay (NY)
$199.70
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

10.7K
Services in NY
587
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in New York

Provider Medicare Services
Scherr, Douglas MD $80.42 279
Schiff, Jonathan MD $76.06 198
Huang, William M.D. $78.46 131
Caplan, Laura RPA-C $60.95 127
Lewis, James PA $70.04 116
Safir, Ilan M.D. $83.93 110
Murray, Katie D.O. $83.22 100
Wysock, James MD $82.91 99
White, Ryan MD $62.25 83
Kahn, Scott MD $74.72 82
Douenias, Robert MD $65.00 82

New York Pricing in Context

In New York, CPT code 51720 (Instillation Of Anti-Cancer Drug Into Bladder) carries an average Medicare payment of $66.85 — 10% above the national benchmark of $60.79. 587 providers across the state submitted claims for this procedure in 2023, performing 10.7K total services. Individual payments in NY ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in New York is $490.40, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because New York sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Urinary Surgery procedures, the estimated commercial insurance price in New York lands near $216.14, with self-pay cash prices typically around $199.70. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Instillation Of Anti-Cancer Drug Into Bladder cost in New York?

The average Medicare payment for Instillation Of Anti-Cancer Drug Into Bladder in New York is $66.85, which is 10% above the national average of $60.79. Providers in NY typically bill $490.40 for this procedure.

What does Instillation Of Anti-Cancer Drug Into Bladder cost with insurance in New York?

With commercial insurance in New York, Instillation Of Anti-Cancer Drug Into Bladder costs an estimated $216.14. Without insurance, the estimated cash price is $199.70. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Instillation Of Anti-Cancer Drug Into Bladder in New York?

587 providers in New York billed Medicare for Instillation Of Anti-Cancer Drug Into Bladder in 2023, performing 10.7K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Instillation Of Anti-Cancer Drug Into Bladder cheaper in New York than the national average?

No — Instillation Of Anti-Cancer Drug Into Bladder costs 10% above the national average in New York. The state average Medicare payment is $66.85 compared to $60.79 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial